ADIL

Adial is a single-asset, clinical-stage biopharma with zero product revenue in its history and an accumulated deficit of $90.0M as of FY2025. Its entire value rests on AD04 for alcohol use disorder, which — after the ONWARD Phase 3 read only in genetic subgroups — now requires TWO additional Phase 3 trials per Q3-2025 regulatory feedback. That is years of spend and binary regulatory risk before any revenue is even possible, and the MD&A concedes approval 'will take a number of years and is subject to significant uncertainty.'

The balance sheet cannot fund that path. Management explicitly states cash of $5.88M is 'not expected to be sufficient for the planned Phase 3 clinical trials or to fund operations for the twelve months from the date of filing' and runs out 'into the second half of 2026' — an unambiguous going-concern warning. With operating cash flow of -$6.49M, the company burns roughly its entire cash balance in a year and survives only through 'a combination of equity offerings, debt financings' it 'may be unable to raise... on favorable terms or at all.' The 1-for-25 reverse split effected February 2026 (shares now just 1.43M, down 78.3% YoY) is the fingerprint of chronic dilution and a Nasdaq listing under pressure; the diluted EPS of -$11.93 is a split-adjusted artifact, not a sign of scale.